Elutia Inc (ELUT)

$3.7

-0.05

(-1.33%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $3.67
    $3.95
    $3.70
    downward going graph

    0.81%

    Downside

    Day's Volatility :6.97%

    Upside

    6.21%

    downward going graph
  • $1.14
    $5.24
    $3.70
    downward going graph

    69.19%

    Downside

    52 Weeks Volatility :78.24%

    Upside

    29.39%

    downward going graph

Returns

PeriodElutia IncIndex (Russel 2000)
3 Months
-15.14%
0.0%
6 Months
26.93%
0.0%
1 Year
160.56%
0.0%
3 Years
159.92%
-21.1%

Highlights

Market Capitalization
127.7M
Book Value
- $2.27
Earnings Per Share (EPS)
-3.09
Wall Street Target Price
10.0
Profit Margin
-261.08%
Operating Margin TTM
-98.89%
Return On Assets TTM
-29.16%
Return On Equity TTM
0.0%
Revenue TTM
25.0M
Revenue Per Share TTM
1.12
Quarterly Revenue Growth YOY
-0.8999999999999999%
Gross Profit TTM
19.2M
EBITDA
-18.7M
Diluted Eps TTM
-3.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.62
EPS Estimate Next Year
-1.1
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Elutia Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 170.27%

Current $3.70
Target $10.00

Company Financials

FY19Y/Y Change
Revenue
42.9M
-
Net Income
-11.9M
-
Net Profit Margin
-27.83%
-
FY20Y/Y Change
Revenue
42.7M
↓ 0.51%
Net Income
-21.8M
↑ 82.8%
Net Profit Margin
-51.13%
↓ 23.3%
FY21Y/Y Change
Revenue
47.4M
↑ 11.03%
Net Income
-24.8M
↑ 13.78%
Net Profit Margin
-52.4%
↓ 1.27%
FY22Y/Y Change
Revenue
23.8M
↓ 49.68%
Net Income
-32.9M
↑ 32.48%
Net Profit Margin
-137.94%
↓ 85.54%
FY23Y/Y Change
Revenue
24.7M
↑ 3.76%
Net Income
-43.7M
↑ 32.71%
Net Profit Margin
-176.42%
↓ 38.48%
Q1 FY23Q/Q Change
Revenue
13.1M
↑ 3.04%
Net Income
-8.0M
↑ 46.58%
Net Profit Margin
-61.1%
↓ 18.15%
Q2 FY23Q/Q Change
Revenue
10.3M
↓ 21.1%
Net Income
-10.6M
↑ 33.2%
Net Profit Margin
-103.16%
↓ 42.06%
Q3 FY23Q/Q Change
Revenue
6.1M
↓ 40.49%
Net Income
-9.7M
↓ 8.23%
Net Profit Margin
-159.08%
↓ 55.92%
Q4 FY23Q/Q Change
Revenue
5.9M
↓ 4.11%
Net Income
-15.3M
↑ 57.14%
Net Profit Margin
-260.7%
↓ 101.62%
Q1 FY24Q/Q Change
Revenue
6.7M
↑ 13.94%
Net Income
-18.0M
↑ 17.48%
Net Profit Margin
-268.81%
↓ 8.11%
Q2 FY24Q/Q Change
Revenue
6.3M
↓ 6.02%
Net Income
-28.2M
↑ 56.61%
Net Profit Margin
-447.94%
↓ 179.13%
FY19Y/Y Change
Total Assets
44.8M
-
Total Liabilities
99.9M
-
FY20Y/Y Change
Total Assets
82.8M
↑ 84.96%
Total Liabilities
62.0M
↓ 37.95%
FY21Y/Y Change
Total Assets
67.2M
↓ 18.89%
Total Liabilities
53.6M
↓ 13.44%
FY22Y/Y Change
Total Assets
68.8M
↑ 2.49%
Total Liabilities
73.9M
↑ 37.7%
FY23Y/Y Change
Total Assets
43.4M
↓ 36.92%
Total Liabilities
82.0M
↑ 11.04%
Q1 FY23Q/Q Change
Total Assets
60.6M
↓ 11.93%
Total Liabilities
72.8M
↓ 1.45%
Q2 FY23Q/Q Change
Total Assets
52.3M
↓ 13.69%
Total Liabilities
74.5M
↑ 2.27%
Q3 FY23Q/Q Change
Total Assets
54.6M
↑ 4.3%
Total Liabilities
84.1M
↑ 12.89%
Q4 FY23Q/Q Change
Total Assets
43.4M
↓ 20.43%
Total Liabilities
82.0M
↓ 2.41%
Q1 FY24Q/Q Change
Total Assets
35.4M
↓ 18.57%
Total Liabilities
85.7M
↑ 4.43%
Q2 FY24Q/Q Change
Total Assets
41.9M
↑ 18.5%
Total Liabilities
106.2M
↑ 24.03%
FY19Y/Y Change
Operating Cash Flow
-7.2M
-
Investing Cash Flow
-577.0K
-
Financing Cash Flow
8.0M
-
FY20Y/Y Change
Operating Cash Flow
-13.4M
↑ 85.95%
Investing Cash Flow
-640.0K
↑ 10.92%
Financing Cash Flow
51.0M
↑ 539.39%
FY21Y/Y Change
Operating Cash Flow
-15.6M
↑ 16.25%
Investing Cash Flow
-369.0K
↓ 42.34%
Financing Cash Flow
6.9M
↓ 86.51%
FY22Y/Y Change
Operating Cash Flow
-21.9M
↑ 40.24%
Investing Cash Flow
-540.0K
↑ 46.34%
Financing Cash Flow
9.0M
↑ 30.8%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.4M
↓ 54.45%
Investing Cash Flow
-85.0K
↓ 36.57%
Financing Cash Flow
-19.0K
↓ 100.13%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.4M
↑ 0.0%
Investing Cash Flow
-85.0K
↑ 0.0%
Financing Cash Flow
-19.0K
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Elutia Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Elutia Inc
Elutia Inc
-13.95%
26.93%
160.56%
159.92%
159.92%
Stryker Corporation
Stryker Corporation
-3.96%
4.86%
37.89%
38.64%
67.22%
Boston Scientific Corp.
Boston Scientific Corp.
4.55%
29.15%
75.89%
108.42%
129.39%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-0.57%
-23.62%
-3.74%
-37.55%
-9.81%
Abbott Laboratories
Abbott Laboratories
-0.24%
6.64%
27.79%
-0.75%
45.48%
Medtronic Plc
Medtronic Plc
-0.71%
11.38%
24.18%
-27.09%
-16.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Elutia Inc
Elutia Inc
NA
NA
NA
-2.62
0.0
-0.29
NA
-2.27
Stryker Corporation
Stryker Corporation
39.69
39.69
2.6
12.01
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
70.81
70.81
2.12
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.82
26.82
3.64
2.61
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
36.63
36.63
4.23
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
29.75
29.75
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Elutia Inc
Elutia Inc
Buy
$127.7M
159.92%
NA
-261.08%
Stryker Corporation
Stryker Corporation
Buy
$135.5B
67.22%
39.69
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$128.3B
129.39%
70.81
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.0B
-9.81%
26.82
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$202.0B
45.48%
36.63
13.65%
Medtronic Plc
Medtronic Plc
Buy
$113.3B
-16.93%
29.75
12.06%

Insights on Elutia Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.69M → 6.29M (in $), with an average decrease of 6.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -9.74M → -28.18M (in $), with an average decrease of 43.7% per quarter

Company Information

aziyo was created by highcape partners and tissue banks international with the mission of restoring health and mobility to the greatest number of patients. our vision for aziyo is to impact healthcare as the premier partner in innovation of new solutions that realize the potential of regenerative medicine. honoring the gift from those who selfishly give the precious gift of donation to those who receive it, we are committed to honoring the lives of these brave individuals and their families everyday. whether you need a traditional bone graft, a processed osteobiologic, or a custom musculoskeletal tissue product, aziyo is committed to innovating new solutions that help fulfill the promise of regenerative medicine. at aziyo, we foster a collaborative environment where we deliver best-in-class solutions and operational excellence to our customers each and every day.

Organization
Elutia Inc
Employees
54
CEO
Dr. C. Randal Mills Ph.D.
Industry
Miscellaneous

Discover More

FAQs